Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 37, 2002 - Issue 2
Submit an article Journal homepage
19
Views
48
CrossRef citations to date
0
Altmetric
Research Article

Effect of Combined Interferon-α Induction Therapy and Ribavirin on Chronic Hepatitis C Virus Infection: a Randomized Multicentre Study

K. Bjøro
,
H. Bell
,
K. B. Hellum
,
K. Skaug
,
N. Raknerud
,
P. Sandvei
,
B. Døskeland
,
A. Maeland
,
S. Lund-Tønnesen
&
B. Myrvang
 show all
Pages 226-232 | Published online: 08 Jul 2009

  • Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1493-9.
  • Reichard O, Foberg U, Fryden A, Norkrans G, Schvarcz R, Sonnerborg A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon alpha 2b for 60 weeks. Hepatology. 1994:19:280-5.
  • McHutchison JG, Gordon SC, Schiff ER, Shiftman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy. N Engl J Med 1998:339:148592.
  • Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interfere) n alpha2b plus ribaviri n for 48 weeks or for 24 weeks versus Interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998;352:1426-32.
  • Craxi A, Di Marco V, Lo Iacono O, Almasio P, Bruno R, Camma C, et al. Transfusion-associated chronic hepatitis C: alpha-n1 interferon for 6 vs. 12 months. J Hepatol 1996;24:53946.
  • Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351:83-7.
  • Lam NP, Neumann AU, Gretch DR, Wiley TE, Perdson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997;26:22631.
  • Ouzan D, Babany G, Valla D, Opolon P. Comparison of high initial and fixed-dose regimens of interferon-alpha2 a in chronic hepatitis C: a randomized controlled trial. French Multicenter Interferon Study Group. J Viral Hepatit 1998;5:53-9.
  • Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-7.
  • Reddy RK, Layden T, Hollinger B. Interferon alfacon-1 induction therapy: a multicenter trial in subjects with chronic hepatitis C virus infection. Hepatology 2000;32 Suppl 4:837A.
  • Sjogren MH, Holtzmuller C, Sjogren W. Failure of interferon induction dosing to alter sustained response rates in patients with chronic hepatitis C. Gastroenterology 2000;! 18 Suppl 4: 6739A.
  • Bell H, Helium K, Harthug S, Maeland A, Ritland S, Myrvang B, et al. Genotype, viral load and age as independent predictors of treatment outcome of interferon-alph a 2a treatment in patients with chronic hepatitis C. Construct group. Scand J Infect Dis 1997:29:17-22.
  • Björo K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemi a after treatment with contaminated immune globuline. N Engl J Med 1994:331:1607-11.
  • Garson JA, Ring CJA, Tuke PW. Improvement of HCV genom detection with 'short' PCR products. Lancet 1991:338:1466-7.
  • Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1982;5:431-8.
  • Tong MJ, Blatt LM, McHutchison JG, Co RL. Conrad A. Prediction of response during Interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997;26:1640-5.
  • Brouwer JT, Hansen BE, Niesters HGM, Schalm SW. Early prediction of response in Interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol 1999;30:192-8.
  • Rubbia-Brandt K, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C viras genotype 3. J Hepatol 2000;33:106-15.
  • Castro FJ, Esteban JI, Sauleda S, Viladomiu L, Dragon EA, Esteban R, et al. Utility of early testing for HCV viremia as predictive factor of sustained response during Interferon or interferon plus ribavirin treatment. J Hepatology. 2000;32:843-9.
  • Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 199726 Suppl 1:122S-7S.
  • Tsubota A, Chayana K, Dceda K, Yasuji A, Koida I, Saitoh S, et al. Factors predictive of response to Interferon-a therapy in hepatitis C viras infection. Hepatology 1994;19:1088-94.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.